Grifols delivers COVID-19 immunotherapy for clinical trials
Grifols has delivered the first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials, which will be conducted this summer. Read More
AI Therapeutics begins COVID-19 phase II trial
AI Therapeutics has announced the start of a phase II trial for a COVID-19 treatment. Read More
Cerevel, Cyclica partner on AI-based drug discovery
Cerevel Therapeutics and Cyclica have announced a research collaboration that will use artificial intelligence (AI) to develop new neurological medicines. Read More
Immunic begins phase II trial of COVID-19 immunotherapy
Immunic has enrolled the first patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase inhibitor, in combination with the neuraminidase inhibitor oseltamivir (Tamiflu). Read More
Carisma advances macrophage immunotherapy
Carisma Therapeutics' engineered macrophage immunotherapy has cleared an investigational new drug application through the U.S. Food and Drug Administration. The company intends to initiate a phase I clinical trial for the candidate this year. Read More
Amyris partners with IDRI on scalable vaccine platform
Amyris and the Infectious Disease Research Institute (IDRI) have inked a binding term sheet for the development of a planned COVID-19 RNA vaccine technology platform. Read More
Moderna begins phase III testing of COVID-19 vaccine
Moderna has begun a phase III clinical trial evaluating its messenger RNA (mRNA)-1273 COVID-19 vaccine candidate. The trial is expected to enroll approximately 30,000 healthy adult volunteers. Read More
Cel-Sci reports positive early results with COVID-19 LEAPS conjugate
Cel-Sci completed animal testing using its Ligand Epitope Antigen Presentation System (LEAPS) COVID-19 conjugate, which means the firm can now move into animal challenge studies with the live SARS-CoV-2 virus. Read More
Exonbio launches SARS-CoV-2 rabbit mAbs
Exonbio debuted its SARS-CoV-2 nucleocapsid recombinant monoclonal antibodies for the global in vitro diagnostics and research communities. Read More
Novavax, Fujifilm begin large-scale manufacturing of COVID-19 vaccine
Novavax and Fujifilm Diosynth have signed an agreement covering the bulk manufacture of Novavax's COVID-19 vaccine candidate, NVX-CoV2373, at Fujifilm's Morrisville, NC, facility. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
